The Association of Devbhumi Pharma Industries (ADPI), Uttarakhand, has hosted an interactive meet in Haridwar bringing together pharma professionals managing quality, regulatory and manufacturing functions to discuss vital topics related to pharmacopoeia standards, quality considerations, and the revision of Schedule M.

Held at the Hotel Hyphen Grand, Sidcul, Haridwar on October 14, 2023, the event was graced by Dr. Rajeev Singh Raghuvanshi, Secretary cum Scientific Director at the Indian Pharmacopoeia Commission (IPC) and Drugs Controller General of India (DCGI), Central Drugs Standard Control Organization (CDSCO) as the Chief Guest and Tajber Singh, Drug Controlling and Licensing Authority, Uttarakhand as the Guest of Honour.

Dr. Raghuvanshi, in his address, praised the efforts of Uttarakhand pharma manufacturers and acknowledged the changing global perspective in the pharmaceutical industry.

He highlighted the importance of updating the industry in collaboration with global regulators. Dr. Raghuvanshi emphasised the critical aspects of pharmacopoeia standards and quality considerations, stressing that it is the industry’s responsibility to execute the provisions of IPC 2022 and timely implementation of the revised Schedule M notification.

He underscored that quality should never be compromised for cost and called for active participation from the pharmaceutical community to ensure India as “Quality Pharmacy of the World”.

Additionally, Dr. Raghuvanshi announced a significant shift towards technology-based systems, revealing plans to create a complete digital platform integrating the Central and State regulatory systems, along with necessary connections to other relevant bodies. This digital platform will ensure a single window for regulatory processes. He further emphasised the increased alignment of state and the central regulatory system, by organising regular meetings for better coordination.

Dr. Raghuvanshi summarised his thoughts by invoking the thoughts among the participants that both regulators and manufacturers must align to uphold the image of Bharat as a Quality conscious manufacturer of the world. This will ensure that we remain the global leader in quality manufacturing. He emphasised that to implement required compliance measures, each manufacturer must ensure “Manufacturing par excellence” and welcome for inspection/audit, any time and every time to ensure the implementation of QMS.

Tajber Singh added regional perspectives and regulatory updates to the discussions. He highlighted DCGI’s objective to ensure the highest quality drugs with utmost standards, ensuring minimal disruption to stakeholders. However, he strongly emphasised there will be no compromise of quality manufacturing and each manufacturer must ensure 100% compliance.

Sandeep Jain, chairman of ADPI and Joint Director of Akums Drugs & Pharmaceuticals Limited, who facilitated the event, emphasised the importance of the pharmaceutical industry and indirectly contributed to employment opportunities.

He proudly lauded the pharmaceutical industry’s noble role during the Covid-19 pandemic, ensuring stable pricing and providing essential medicines. He reiterated the industry’s commitment to delivering competitive prices and top-quality products and commended the industry stakeholders for their significant contributions to corporate social responsibility.

Pramod Kalani, vice chairman, ADPI, in his vote of thanks, ensured that Uttrakhand manufactures will uphold the image of our country as quality manufacturers of the world.

This interactive meeting proved to be an important platform for discussing pharmacopoeia standards, quality considerations, and the revision of Schedule M, promoting alignment with global standards and best manufacturing practices. The question answer session by CDSCO and IPC team clarified the points put forward by delegates and gave the required guidance on implementation of IP 2022.

Akums Drugs & Pharmaceuticals Limited as the sponsor extended generous support and made it possible to bring together key stakeholders and experts to exchange knowledge and insights on this crucial subject.

The IPC interactive meet was a day filled with invaluable discussions and the sharing of knowledge and expertise. It served as a platform for industry professionals, regulators, and experts to collaborate, understand and address the evolving landscape of pharmaceutical standards and regulatory compliance.